Loading organizations...
§ Private Profile · Herzliya, Tel Aviv, Israel
Neuroscience technology developer assessing brain network functionality for healthcare providers treating neurological and psychological disorders.
Based in Herzliya, Israel, ElMindA develops the Brain Network Activation (BNA) platform, a neuroscience technology utilizing multi-channel EEG-ERP to objectively assess brain network functionality for neurological and psychological disorders. The company's FDA-cleared and CE-marked medical device maps brain activity over time to enhance diagnosis and treatment capabilities for healthcare providers operating across the United States and Europe. ElMindA has raised $43 million in total venture capital funding, which includes an oversubscribed $28 million Series C round completed in 2015. To date, the organization has invested approximately $60 million into the ongoing development of its core diagnostic technology. The enterprise is backed by prominent institutional investors including Shanda Group, The Kraft Group, Wexford Capital, and OurCrowd, and its BNA software was recently integrated into Firefly Neuroscience. ElMindA was originally founded in 2006 by Professor Amir Geva.
ElMindA has raised $28.0M across 1 funding round.
ElMindA has raised $28.0M in total across 1 funding round.
ElMindA has raised $28.0M across 1 funding round. Most recently, it raised $28.0M Series C in November 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 16, 2015 | $28M Series C | — | Healthcrest, OurCrowd, Palisade Capital Management, Tianqiao Chen 陈天桥, Robert Kraft, Wexford Capital, Bill Hambrecht | Announced |
ElMindA has raised $28.0M in total across 1 funding round.
ElMindA's investors include HealthCrest, OurCrowd, Palisade Capital Management, Tianqiao Chen 陈天桥, Robert Kraft, Wexford Capital, Bill Hambrecht.